Press Release: January 19, 2023

CATEGORY: Philanthropy News

Amgen Joins Gilead Sciences as a Program Supporter

Applications Now Open for Physicians and Medical Students

PRINCETON, N.J.--(BUSINESS WIRE)-- The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) established by the Bristol Myers Squibb Foundation (BMSF) today announced that Amgen, a global biotechnology company, has committed to contribute $8 million over the next four years. This contribution will enable the program to reach additional physicians and medical students, further expanding the initiative that aims to extend the reach of clinical trials in underserved patient populations in U.S. communities.

The Winn Award Program has so far trained 114 early-stage investigator physicians, and it has provided an immersive experience in community-based clinical research to 44 medical students who are from diverse racial and ethnic backgrounds. It is now accepting applications from physicians for the third cohort of its Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA) and from medical students for the second cohort of its Robert A. Winn Diversity in Clinical Trials: Clinical Investigator Pathway Program (Winn CIPP) Award. With the additional support from Amgen, it is set to reach more than 300 diverse and community-oriented clinical investigators and 300 diverse medical students by 2027.

“With the skills, experience and networks they will gain from participation in the Winn Award Program, these extraordinary physicians and students will make a significant difference in how healthcare is delivered in the U.S.,” said Jude Ngang, Executive Director, and leader of the Amgen Representation in Clinical Research (RISE) program. “Supporting physicians and medical students dedicated to health equity and emphasizing the need for increasing diversity in clinical trials early in their careers is an important step toward improving the health of all people.”

Diversity in clinical trials is a longstanding challenge in healthcare, and currently close to 80% of participants in clinical research trials are white, according to the Food and Drug Administration. Lack of diversity in clinical trials hinders the ability to eliminate health disparities and ensure medicines are safe and effective for all patients. To address this issue, the BMSF created the Winn Award Program in 2020 as part of its commitment to health equity, inclusion and diversity. The BMSF chose Virginia Commonwealth University (VCU) as the program implementation partner and the American Association for Cancer Research (AACR) as a curriculum partner to deliver The Robert A. Winn – AACR Design and Implementation of Clinical Trials Workshop, the first training the Winn CDA scholars receive. The program is named in honor of Robert A. Winn, M.D., Director and Lipman Chair in Oncology, VCU Massey Cancer Center and Chair of the Winn Award Program National Advisory Committee.

“It is no secret that the current state of clinical research does not reflect the diversity of the U.S. population,” said John Damonti, President, Bristol Myers Squibb Foundation (BMSF). “Substantial, lasting change can be accomplished only if everyone is a part of this movement in diversifying healthcare. As we strive to ensure that safe and effective medicines and therapies are available for all across the nation, we are honored to have Amgen serve as a supporter of the Winn Award Program in achieving this vision.”

The BMSF pledged $100 million to support 250 Winn CDAs and 250 Winn CIPPs over the span of the program. In 2022, Gilead Sciences committed $14 million of support, including 10 Winn CDAs and 10 Winn CIPPs per year for four years.

“Gilead is pleased to welcome Amgen to the Winn Award Program as a new and very appreciated supporter,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “At Gilead, we’re committed to creating a healthier world for everyone. By investing in the training and development of clinical trial scientists, we’re recognizing and supporting transformative medical breakthroughs while expanding reach to more patient populations and communities.”

The Winn Award Program currently offers two awards: the Winn CDA, a two-year program designed to support diverse physicians and those who have demonstrated commitment to increasing diversity in clinical trial research within their local communities, and the Winn CIPP, a six-week summer externship during which diverse medical students are provided an immersive experience in community-based clinical research. The Winn Award Program encourages others in the healthcare industry to consider participating as faculty and/or sponsors. Interested parties can learn more about the program at diversityinclinicaltrials.org and contact the team at winnawardinfo@vcu.edu.

About the Bristol Myers Squibb Foundation

The Bristol Myers Squibb Foundation, an independent charitable organization, focuses on communities most at risk of suffering the impacts of serious diseases in regions of the world that are hardest hit. It empowers partners to develop and test innovative solutions to advance health equity and improve access to quality healthcare for patients. Grant making focuses on cancer, cardiovascular disease, and immunologic disease, as well as clinical trial diversity in the United States, and prevalent cancers in nine African countries, Brazil and China. The mission of the Bristol Myers Squibb Foundation is to promote health equity and improve the health outcomes of populations disproportionately affected by serious diseases by strengthening healthcare worker capacity, integrating medical care and community-based supportive services and mobilizing communities in the fight against disease. For more information, visit Bristol Myers Squibb Foundation (bms.com).

About Virginia Commonwealth University

Virginia Commonwealth University (VCU) is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls nearly 29,000 students in 238 degree and certificate programs in the arts, sciences and humanities. Twenty-three of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 11 schools and three colleges. For more, please visit vcu.edu.

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 54,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 130 countries and territories. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting. In addition, the AACR publishes 10 prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Corporate Philanthropy-News

Media: media@bms.com

Source: Bristol Myers Squibb 

 The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027. 

PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb Foundation (BMSF), together with its partners, National Medical Fellowships (NMF) and the American Association for Cancer Research (AACR), today announced a new name for the $100 million, five-year initiative launched in 2020 to increase diversity in clinical trials: The Robert A. Winn Diversity in Clinical Trials Award Program. Also, the program welcomed a donation of $14 million over the next four years from new program supporter, Gilead Sciences, Inc.

The program, created as one of a number of commitments to health equity and diversity and inclusion made in 2020 by the BMSF and its donor Bristol Myers Squibb, has been named in honor of Robert A. Winn, M.D., Director, Massey Cancer Center, Virginia Commonwealth University. Winn is the first African-American director of a National Cancer Institute (NCI)-designated cancer center, and the recipient of numerous honors and awards, such as the NCI Center to Reduce Cancer Health Disparities Continuing Umbrella of Research Experiences Program Lifetime Achievement Award. Serving as Chair of the National Advisory Committee of the BMSF Diversity in Clinical Trials Career Development Program from its inception, Winn’s guidance was instrumental in shaping the program.“We are proud and overjoyed that Dr. Winn has agreed to put his name on this program,” said John Damonti, president, Bristol Myers Squibb Foundation. “He has been a tireless advocate for the goal of this program -- enabling people of color and underserved populations to benefit more from clinical research. Throughout his distinguished career, he has demonstrated extraordinary commitment to community-engaged research focused on eliminating health inequities. It is largely due to his leadership, expertise, and passion that the program became a reality.”

“I am honored to be such a small part of a big program that will have tremendous impact for years to come,” said Winn.

“We congratulate Dr. Winn on this richly deserved honor,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The AACR and the cancer research community as a whole have benefited greatly from his leadership on issues of diversity, equity, and community engagement. His innovative efforts are helping to transform cancer research into a more inclusive field of investigation that supports minority scientists and physicians and understands the urgency of addressing the disparities that have impacted underserved communities for far too long. It is fitting to name this exciting, impactful program after him, and we were pleased to celebrate him and our partnership with BMSF and NMF yesterday at the AACR Annual Meeting Opening Ceremony in New Orleans.”

Developing world-class community-oriented clinical researchers

The Robert A. Winn Diversity in Clinical Trials Award Program includes two awards: the Robert A. Winn Career Development Award for early-stage investigator physicians who are from diverse backgrounds and/or committed to increasing diversity in clinical trials, and the Robert A. Winn Clinical Investigator Pipeline Program Award for medical students who are underrepresented in medicine (URM). The BMSF has committed to support 250 Winn Career Development Awards and 250 Winn Pipeline Awards. In addition, Gilead Sciences has committed to support 10 of each award per year for the next four years.“This program is already developing the capabilities of a diverse group of clinical researchers who are committed to engaging their communities and ensuring that all impacted people are represented in clinical trials, which is essential for a full understanding of how medicines work,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “Gilead is proud to support this work that builds on our existing efforts to ensure that greater inclusion and diversity are embedded into the design of clinical trials and to put the needs of patients first.”

The first cohort of Winn Career Development Award Scholars entered the program in November 2021. These physicians are from 22 states across the U.S. and include 34 women and 18 men who represent a diverse cross section of races and ethnicities, as well as a range of experiences in the therapeutic focus areas of cancer (hematologic and solid tumors), immunologic disorders and cardiovascular diseases. Their two-year participation in the program began with an intensive AACR educational workshop on “best-in-class” clinical trial design, followed by training in the skills and competencies needed to effectively engage with communities to foster trusted relationships aimed at recruiting diverse clinical trial participants. The Winn Career Development Award Scholars are paired in mentoring relationships with established clinical investigators, and also serve as mentors to URM medical students in the Winn Pipeline Award program.

“This program is a game-changer in the fight to advance health equity and to make both the field and practice of clinical research more inclusive. It provides a critical on-ramp for physicians and students underrepresented in medicine to become clinical investigators and lead community-oriented research that benefits all populations,” said Michellene Davis, Esq, President & CEO of National Medical Fellowships. “Community-oriented research, led by diverse clinical trialists, is essential to help dismantle systemic and structural racism and to overcome the well-earned historical and present-day mistrust that communities of color have of medical research. The mentorship woven into the program is essential to career advancement and professional resiliency, which are especially important for those underrepresented in medicine.”

For more information about The Robert A. Winn Diversity in Clinical Trials Award Program established by the Bristol Myers Squibb Foundation, visit diversityinclinicaltrials.org.

About the Bristol Myers Squibb Foundation

The Bristol Myers Squibb Foundation, an independent charitable organization, focuses on communities most at risk of suffering the impacts of serious diseases in regions of the world that are hardest hit. It empowers partners to develop and test innovative solutions to advance health equity and improve access to quality healthcare for patients. Grant making focuses on cancer, cardiovascular disease, and immunologic disease, as well as clinical trial diversity in the United States, and prevalent cancers in nine African countries, Brazil and China. The mission of the Bristol Myers Squibb Foundation is to promote health equity and improve the health outcomes of populations disproportionately affected by serious diseases by strengthening healthcare worker capacity, integrating medical care and community-based supportive services and mobilizing communities in the fight against disease. For more information, visit Bristol Myers Squibb Foundation (bms.com).

About National Medical Fellowships

Seeking to empower and support aspiring physicians and health professionals underrepresented in medicine to contribute to the health of our nation, National Medical Fellowships’ mission is to provide scholarships and support for students underrepresented in medicine and the health professions. Founded in 1946, NMF is one of America’s first diversity organizations. Today, as the only national organization solely dedicated to providing scholarships to medical and health professions students in all groups underrepresented in healthcare, NMF is reducing healthcare disparities by creating new generations of clinicians and healthcare leaders who are dedicated to realizing health equity. NMF is supported by a national network of more than 32,000 Alumni who serve tens of millions of patients annually. Together we continue to move health equity forward as we build the next generation of diverse healthcare leaders. For more information about NMF, visit nmfonline.org.

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure all cancers. AACR membership includes more than 50,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 129 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the understanding, prevention, early detection, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops—the largest of which is the AACR Annual Meeting, with more than 74,000 attendees at the 2020 virtual meetings and more than 22,500 attendees for past in-person meetings. In addition, the AACR publishes 10 prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and cancer-related sciences in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

philanthropy-news

Media: 

media@bms.com

Source: Bristol Myers Squibb Twitter 

There's a Stunning Lack of Diversity in Clinical Trials. Can Philanthropy Move the Needle?

Calls for equity in our healthcare system are growing louder every day—from the need to boost access to care, to the push for more doctors of color. For years, there has also been a stunning lack of diversity in clinical trials, an area of medicine with a low profile but a tremendous impact. 

One big pharmaceutical company’s foundation is now tackling this issue, which has proven stubbornly resistant to change. The Bristol Myers Squibb Foundation, in partnership with National Medical Fellowships, just announced a new push to improve diversity in clinical trials. 

The Diversity in Clinical Trials Career Development Program will train 250 new clinical investigators who are racially and ethnically diverse or have shown a commitment to diversity in medical trials. The program also seeks to introduce minority medical students to clinical research career pathways and increase the number of clinical trials located in communities of color and underserved areas of the country. 

The program is part of a five-year, $300 million commitment on the part of global pharmaceutical giant Bristol Myers Squibb and its foundation to “accelerate and expand health equity, and diversity and inclusion efforts.” Out of that pledge, $100 million will support the clinical trials initiative.

A moral and scientific imperative

Today, close to 80% of participants in clinical research trials are white, according to the Food and Drug Administration; only 7% are Black. This homogeneity is consistent across many areas of medical research: A 2019 report published in JAMA Oncology found that Black and Hispanic people were severely underrepresented in cancer clinical trials, for example, and STAT reported that Hispanics make up just 0.54% of participants in genome-wide association studies. 

This issue isn’t new. The National Institutes of Health Revitalization Act, passed by Congress in 1993, required the NIH to include more women and people of color in research studies. It was partially successful: The participation of women in clinical trials has increased significantly, but racial diversity continues to lag. 

Diversity in clinical trials isn’t a simple issue of fairness. We now know that individual factors, including race and ethnicity, can and do influence how a person responds to illness and treatment. As researchers put it in a recent report, “To ensure that medical discoveries, new treatments and interventions are applicable to all populations for whom they are intended, appropriately representative clinical trial diversity is a moral, scientific and medical imperative.”

Bristol Myers Squibb Foundation (BMSF) President John Damonti agrees: “We now know that medical treatments don’t work the same way for everyone, and we need to understand that if we are going to provide the best possible care.” 

Barriers to diversity

Diversity in medical trials has been hard to achieve for reasons that range from the historical to the practical. Even when researchers try to diversify their trials, many people of color are reluctant to participate. This mistrust is entirely understandable, given shameful abuses like the Tuskegee experiment, the exploitation of Henrietta Lacks and the forced sterilization of many Blacks, Indigenous people, immigrants and people with disabilities conducted throughout the U.S. into the 20th century.

Damonti points out that the location of clinical trials can also present a barrier. “Many clinical trials are conducted at large urban academic centers,” he says. “These are excellent institutions, but they are not always conducive or welcoming to minority patients, and they’re not necessarily where they get their regular care. Transportation can also be a barrier. And, of course, very few clinical trials are located in rural areas.”

Damonti hopes that BMSF’s partnership with National Medical Fellowships (NMF) will help break down these barriers. NMF, which was founded in 1946, provides scholarships and support to minority students in healthcare. 

“For 70 years, NMF has been a leader in the support of underrepresented minorities in medical schools,” Damonti said. “That is their sweet spot. They have an enormous network of medical students and medical professionals who live in and are able to connect to diverse communities across the country.”  

Perhaps unsurprising, main funders in this space include other pharmaceutical companies and their foundations. Amgen has supported clinical trial diversity, and more recently, Novartis US Foundation made a $25 million commitment to health equity with a focus on making trials more diverse.

Damonti believes BMSF’s approach will be more effective than past efforts. He points out that BMSF has been around for 21 years, and has developed a track record of healthcare philanthropy around the world. This new initiative actually grew out of the foundation’s work treating HIV/AIDS patients in Africa in the 1990s.

“We learned then that to reach people, it couldn’t be done out of New York City,” he said. “To build trust, we had to have staff on the ground who were from the communities where we were working. We’ve seen it through the years of clinical trials: Patients are more likely to participate through the course of a trial and be consistent in their participation if they trust the people treating them. And we’re creating a cadre of professionals that will be continuing this work over the long term.”

“A stake in the ground on health equity”

BMSF was already planning to launch an initiative to improve diversity in clinical trials when the layered crises of 2020 hit—and made the need even more urgent. “We were planning to train a smaller number of investigators,” Damonti said. “Then COVID-19 hit and George Floyd was killed. The company decided they wanted to put a stake in the ground on the issue of health equity. At the foundation, we said, ‘If we really want to move the needle on health equity, let’s make this program more significant.’ And the company agreed.”   

Will BMSF’s approach succeed where other efforts have failed? Damonti himself is hopeful, but waiting to be convinced. The upstream strategy of backing the very people who will be conducting clinical trials is a strategic one, but also takes time and requires a leap of faith.

“Training these investigators is important,” he said. “But if in five years, I tell you, ‘We’ve trained 250 investigators, here they are,’ and they haven’t been able to increase the diversity of clinical trials, then we won’t have achieved our goals.” 

By Connie Matthiessen, Inside Philanthropy 

View Source Version on Endpoints News at: https://www.insidephilanthropy.com/home/2020/12/9/theres-a-stunning-lack-of-diversity-in-clinical-trials-can-philanthropy-move-the-needle?utm_content=buffer3df7b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

Bristol Myers Squibb Foundation and National Medical Fellowships Launch Program to Help Increase Diversity and Inclusion

The Bristol Myers Squibb Foundation and National Medical Fellowships have announced that they have entered into a partnership aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment from Bristol Myers Squibb and the Bristol Myers Squibb Foundation to diversity and inclusion, the partnership will develop a program to extend the reach of clinical trials into underserved patient populations in urban and rural U.S. communities, training and developing 250 new clinical investigators who are racially and ethnically diverse or who have a demonstrated commitment to increasing diversity in clinical trials.

“Clinical research is necessary to generate evidence demonstrating the efficacy and safety of new treatments,” said Robert Winn, MD, Director, Massey Cancer Center, Virginia Commonwealth University, who is serving as chair of the national advisory committee of the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program. “While the patient response to medical therapies may differ across racial and ethnic subgroups, clinical trials often fail to represent the demographic diversity of the populations that these products aim to serve. I am proud to serve as an advisor to this program, which will support improvements toward diverse representation in clinical research and promote health equity.”

View Source Version on Applied Clinical Trials at: https://www.appliedclinicaltrialsonline.com/view/bristol-myers-squibb-foundation-and-national-medical-fellowships-launch-program-to-help-increase-diversity-and-inclusion